The VEGF Treatment of AMD Switch Study (The vTAS Study)

The VEGF Treatment of AMD Switch Study (The vTAS Study)

To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT). Prospective, open-label study. Eighteen patients (19 eyes) with CNV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) Pa.), 2017-11, Vol.6 (6), p.481-487
Hauptverfasser: Curry, Beverley, Bylsma, Guy, Hewitt, Alex W, Verma, Nitin
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Angiogenesis Inhibitors - therapeutic use
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - pathology
Drug Substitution
Female
Humans
Intravitreal Injections
Macular Edema - pathology
Male
Middle Aged
Prospective Studies
Ranibizumab - therapeutic use
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Subretinal Fluid - metabolism
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT). Prospective, open-label study. Eighteen patients (19 eyes) with CNV being treated with monthly ranibizumab, with persistent fluid on OCT, were switched to intravitreal aflibercept injections at intervals of up to 8 weeks. The primary outcome was the proportion of patients maintaining vision [
ISSN:2162-0989
2162-0989
DOI:10.22608/APO.2017364